Kimia Farma posts unaudited net profit of Rp54.07 billion
PT Kimia Farma (Persero) Tbk (KAEF) recorded an unaudited net profit of Rp54.07 billion in the first half of 2026.
“This achievement marks a positive turnaround compared to the same period last year, when the company still recorded a net loss of Rp135.61 billion,” said President Director of PT Kimia Farma (Persero) Tbk, Djagad Prakasa Dwialam, in an official statement in Jakarta on Wednesday.
The positive performance was supported by the company’s net sales growth, which reached Rp4.70 trillion, up 7.6 per cent from Rp4.36 trillion in the first half of 2025.
From an operational perspective, the company’s operating profit rose 111.3 per cent to Rp152.21 billion, compared with Rp72.01 billion in the same period last year.
“The positive performance in the first half of 2026 shows that the transformation process is heading in a healthier and more measurable direction. With a healthier business, KAEF has a stronger foundation to support the availability of medicines, healthcare services, and national priority programmes,” he said.
Nevertheless, in the second quarter of 2026, geopolitical dynamics in the Middle East were said to still exert pressure on the company’s performance, particularly through rising prices of raw materials and packaging materials, some of which are still sourced from imports.
The company stated that it continues to monitor developments in the situation, including its impact on supply chain stability and production costs.
Source: jawawa.id (https://jawawa.id/newsitem/kimia-farma-posts-unaudited-net-profit-of-rp54-07-billion-1785909190)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5680471/kimia-farma-bukukan-laba-bersih-unaudited-rp5407-miliar), translated from Indonesian